$ZYME
Zymeworks Inc.

2022 Q4 Form 10-Q Financial Statement

#000193765322000009 Filed on November 08, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $402.5M $2.631M $4.395M
YoY Change 1925.63% -40.14% 66.48%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $30.13M $15.89M $15.47M
YoY Change 414.71% 2.75% -32.2%
% of Gross Profit
Research & Development $52.97M $37.10M $49.89M
YoY Change -3.46% -25.65% -6.79%
% of Gross Profit
Depreciation & Amortization $1.681M $1.551M $1.412M
YoY Change 68.94% 9.84% -29.4%
% of Gross Profit
Operating Expenses $83.10M $52.99M $65.36M
YoY Change 36.86% -18.93% -14.38%
Operating Profit -$50.36M -$60.96M
YoY Change -17.4%
Interest Expense $1.068M $2.581M $1.153M
YoY Change 253.64% 123.85% 0.26%
% of Operating Profit
Other Income/Expense, Net -$27.00K -$98.00K -$4.000K
YoY Change -212.5% 2350.0% -94.29%
Pretax Income $320.4M -$47.88M -$59.82M
YoY Change -890.75% -19.96% -17.62%
Income Tax $11.01M -$29.00K $764.0K
% Of Pretax Income 3.43%
Net Earnings $309.4M -$47.85M -$60.58M
YoY Change -890.33% -21.02% -16.51%
Net Earnings / Revenue 76.88% -1818.55% -1378.36%
Basic Earnings Per Share -$0.72 -$1.17
Diluted Earnings Per Share $4.64 -$0.72 -$1.17
COMMON SHARES
Basic Shares Outstanding 63.00M shares 66.48M shares 51.66M shares
Diluted Shares Outstanding 66.48M shares 52.24M shares

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $492.2M $166.2M $307.8M
YoY Change 94.86% -45.98% -34.78%
Cash & Equivalents $400.9M $96.08M $253.4M
Short-Term Investments $91.32M $70.16M $54.32M
Other Short-Term Assets $19.07M $17.69M $24.08M
YoY Change -4.62% -26.55% 104.07%
Inventory
Prepaid Expenses
Receivables $33.40M $6.728M $4.927M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $544.7M $190.7M $336.8M
YoY Change 88.99% -43.39% -30.89%
LONG-TERM ASSETS
Property, Plant & Equipment $24.71M $49.28M $43.13M
YoY Change -50.35% 14.25% 142.33%
Goodwill $12.02M $12.02M
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments $886.0K $886.0K $886.0K
YoY Change 0.0% 0.0% -96.58%
Other Assets $17.08M $20.78M $7.232M
YoY Change 1.85% 187.26% 53.87%
Total Long-Term Assets $104.0M $109.6M $83.60M
YoY Change 3.08% 31.12% -0.95%
TOTAL ASSETS
Total Short-Term Assets $544.7M $190.7M $336.8M
Total Long-Term Assets $104.0M $109.6M $83.60M
Total Assets $648.7M $300.3M $420.4M
YoY Change 66.71% -28.57% -26.47%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.863M $317.0K $5.046M
YoY Change 51.97% -93.72% 62.77%
Accrued Expenses $81.09M $52.76M $50.08M
YoY Change 43.06% 5.36% 4.33%
Deferred Revenue $2.353M
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $22.00K
YoY Change -100.0%
Total Short-Term Liabilities $95.63M $57.71M $75.43M
YoY Change 33.08% -23.5% -22.16%
LONG-TERM LIABILITIES
Long-Term Debt $124.0K $155.0K $105.0K
YoY Change 24.0% 47.62% 5.0%
Other Long-Term Liabilities $3.101M $61.05M $64.15M
YoY Change -95.34% -4.82% 54.95%
Total Long-Term Liabilities $3.101M $61.21M $64.25M
YoY Change -95.34% -4.74% 54.83%
TOTAL LIABILITIES
Total Short-Term Liabilities $95.63M $57.71M $75.43M
Total Long-Term Liabilities $3.101M $61.21M $64.25M
Total Liabilities $155.8M $120.5M $141.4M
YoY Change 11.23% -14.8% 1.46%
SHAREHOLDERS EQUITY
Retained Earnings -$558.8M -$868.2M
YoY Change -18.2%
Common Stock $1.038B $1.055B
YoY Change 10.55%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $493.0M $179.8M $278.9M
YoY Change
Total Liabilities & Shareholders Equity $648.7M $300.3M $420.4M
YoY Change 66.71% -28.57% -26.47%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income $309.4M -$47.85M -$60.58M
YoY Change -890.33% -21.02% -16.51%
Depreciation, Depletion And Amortization $1.681M $1.551M $1.412M
YoY Change 68.94% 9.84% -29.4%
Cash From Operating Activities $327.4M -$73.02M -$50.79M
YoY Change -748.12% 43.77% 216.23%
INVESTING ACTIVITIES
Capital Expenditures $883.0K $3.792M $5.174M
YoY Change -84.3% -26.71% 95.98%
Acquisitions
YoY Change
Other Investing Activities -$21.18M -$26.64M $47.54M
YoY Change -662.3% -156.03% 18.2%
Cash From Investing Activities -$22.06M -$30.43M $42.37M
YoY Change 1088.21% -171.82% 12.71%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $637.0K $4.593M
YoY Change -86.13% 39.6%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -377.0K 628.0K 4.545M
YoY Change -154.72% -86.18% 40.28%
NET CHANGE
Cash From Operating Activities 327.4M -73.02M -50.79M
Cash From Investing Activities -22.06M -30.43M 42.37M
Cash From Financing Activities -377.0K 628.0K 4.545M
Net Change In Cash 304.9M -102.8M -3.875M
YoY Change -690.05% 2553.29% -115.64%
FREE CASH FLOW
Cash From Operating Activities $327.4M -$73.02M -$50.79M
Capital Expenditures $883.0K $3.792M $5.174M
Free Cash Flow $326.5M -$76.81M -$55.96M
YoY Change -681.61% 37.25% 199.26%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001937653
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q3 us-gaap Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2021Q4 us-gaap Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2022Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
0.001 shares
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-41535
dei Entity Registrant Name
EntityRegistrantName
ZYMEWORKS INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
88-3099146
dei Entity Address Address Line1
EntityAddressAddressLine1
108 Patriot Drive, Suite A
dei Entity Address City Or Town
EntityAddressCityOrTown
Middletown
dei Entity Address State Or Province
EntityAddressStateOrProvince
DE
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19709
dei City Area Code
CityAreaCode
302
dei Local Phone Number
LocalPhoneNumber
274-8744
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
62996314 shares
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
96082000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
201867000 usd
CY2022Q3 us-gaap Short Term Investments
ShortTermInvestments
70160000 usd
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
50741000 usd
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6728000 usd
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
15614000 usd
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
17686000 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
19998000 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
190656000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
288220000 usd
CY2022Q3 zyme Deferred Financing Fee
DeferredFinancingFee
1293000 usd
CY2021Q4 zyme Deferred Financing Fee
DeferredFinancingFee
1214000 usd
CY2022Q3 us-gaap Long Term Investments
LongTermInvestments
886000 usd
CY2021Q4 us-gaap Long Term Investments
LongTermInvestments
886000 usd
CY2022Q3 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
16454000 usd
CY2021Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
12490000 usd
CY2022Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
3028000 usd
CY2021Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
3070000 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
25717000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
22783000 usd
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
23564000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
26987000 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
9021000 usd
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3838000 usd
CY2022Q3 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
17628000 usd
CY2021Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
17628000 usd
CY2022Q3 us-gaap Goodwill
Goodwill
12016000 usd
CY2021Q4 us-gaap Goodwill
Goodwill
12016000 usd
CY2022Q3 us-gaap Assets
Assets
300263000 usd
CY2021Q4 us-gaap Assets
Assets
389132000 usd
CY2022Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
52271000 usd
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
62767000 usd
CY2022Q3 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
830000 usd
CY2021Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
7754000 usd
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4605000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1310000 usd
CY2022Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
0 usd
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
22000 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
57706000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
71853000 usd
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
25334000 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
30923000 usd
CY2022Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
32941000 usd
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
32941000 usd
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2934000 usd
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2748000 usd
CY2022Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1590000 usd
CY2021Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1573000 usd
CY2022Q3 us-gaap Liabilities
Liabilities
120505000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
140038000 usd
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
61694387 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
61694387 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
46633935 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
46633935 shares
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
885349000 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
741147000 usd
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
169262000 usd
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
197710000 usd
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-6659000 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1669000 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-6659000 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-868194000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-683104000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
179758000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
249094000 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
300263000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
389132000 usd
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2631000 usd
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4395000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9989000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6810000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
37097000 usd
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
49893000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
155629000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
144887000 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15892000 usd
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15466000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
43227000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
36707000 usd
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
52989000 usd
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
65359000 usd
us-gaap Costs And Expenses
CostsAndExpenses
198856000 usd
us-gaap Costs And Expenses
CostsAndExpenses
181594000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-50358000 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-60964000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-188867000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-174784000 usd
CY2022Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1125000 usd
CY2021Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
340000 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1863000 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1358000 usd
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
809000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1802000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1279000 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2483000 usd
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1149000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3665000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2948000 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-47875000 usd
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-59815000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-185202000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-171836000 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-29000 usd
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
764000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-112000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
855000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-47846000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-47846000 usd
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-60579000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-60579000 usd
us-gaap Net Income Loss
NetIncomeLoss
-185090000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-185090000 usd
us-gaap Net Income Loss
NetIncomeLoss
-172691000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-172691000 usd
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.72
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.17
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.86
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.35
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.72
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.86
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.66
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
66477016 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51657371 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
64751271 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51483428 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
66478157 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
52238901 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
64756063 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
52125929 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
249094000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
12000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1361000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
-2932000 usd
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
107534000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-72625000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
282444000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4450000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-64619000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
222282000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
107000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
830000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
CY2022Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4385000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-47846000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
179758000 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
409922000 usd
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1962000 usd
CY2021Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1321000 usd
CY2021Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8530000 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-44590000 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
377145000 usd
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
763000 usd
CY2021Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11086000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-67522000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
321472000 usd
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5943000 usd
CY2021Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1759000 usd
CY2021Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10334000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-60579000 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
278929000 usd
us-gaap Net Income Loss
NetIncomeLoss
-185090000 usd
us-gaap Net Income Loss
NetIncomeLoss
-172691000 usd
zyme Depreciation And Amortization On Property And Equipment
DepreciationAndAmortizationOnPropertyAndEquipment
5068000 usd
zyme Depreciation And Amortization On Property And Equipment
DepreciationAndAmortizationOnPropertyAndEquipment
2894000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
486000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2643000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
-483000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
12446000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
4142000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
2604000 usd
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-59000 usd
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-303000 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-250000 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
31000 usd
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
0 usd
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
167000 usd
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
2255000 usd
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
200000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-9163000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-10421000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1417000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
11586000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-11088000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
10713000 usd
zyme Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1586000 usd
zyme Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
647000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-183251000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-141942000 usd
zyme Proceeds From Issuance Of Common Stock Public Offering
ProceedsFromIssuanceOfCommonStockPublicOffering
107534000 usd
zyme Proceeds From Issuance Of Common Stock Public Offering
ProceedsFromIssuanceOfCommonStockPublicOffering
0 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
116000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
5436000 usd
zyme Proceeds From Issuance Of Shares Under Employee Share Purchase Plan
ProceedsFromIssuanceOfSharesUnderEmployeeSharePurchasePlan
1403000 usd
zyme Proceeds From Issuance Of Shares Under Employee Share Purchase Plan
ProceedsFromIssuanceOfSharesUnderEmployeeSharePurchasePlan
2070000 usd
zyme Payments Of Deferred Financing Fees
PaymentsOfDeferredFinancingFees
80000 usd
zyme Payments Of Deferred Financing Fees
PaymentsOfDeferredFinancingFees
172000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
14000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
12000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
108959000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7322000 usd
us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
19542000 usd
us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
-154114000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7802000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7621000 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
4440000 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
40000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-31784000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
146453000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
291000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-430000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-105785000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
11403000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
201867000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
242036000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
96082000 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
253439000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
72000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
21748000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1431000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1649000 usd
us-gaap Nature Of Operations
NatureOfOperations
Nature of Operations<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Zymeworks Inc. (the “Company” or “Zymeworks”) is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks was incorporated on September 8, 2003 under the laws of the Canada Business Corporations Act.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On October 22, 2003, the Company was registered as an extra-provincial company under the Company Act (British Columbia). On May 2, 2017, the Company continued under the Business Corporations Act (British Columbia). </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Since its inception, the Company has devoted substantially all of its resources to research and development activities, including developing its therapeutic platforms, and identifying and developing potential product candidates by undertaking preclinical studies and clinical trials. The Company supports these activities through general and administrative support, as well as by raising capital, conducting business planning and protecting its intellectual property.</span></div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 15, 2022, the Company announced its intention to become a Delaware corporation, subject to receipt of necessary shareholder, stock exchange, and court approvals (the “Redomicile Transactions”). The Redomicile Transactions were completed on October 13, 2022. On October 13, 2022, the Company changed its name to Zymeworks BC Inc. Unless the context otherwise requires or otherwise expressly states, all references in t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">he accompanying</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">interim condensed consolidated financial statements</span> to “Zymeworks,” the “Company,” “we,” “us” and “our” (i) for periods until completion of the the Redomicile Transactions, refer to Zymeworks BC Inc. and its subsidiaries and (ii) for periods after completion of the Redomicile Transactions, refer to Zymeworks Inc. (formerly known as Zymeworks Delaware Inc.) and its subsidiaries. These transactions are described further in note 15.
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of interim condensed consolidated financial statements in accordance with U.S. GAAP requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates, most notably those related to revenue recognition including estimated timing of completion of performance obligations required to meet revenue recognition criteria, accrual of expenses including clinical and preclinical study expense accruals, stock-based compensation, valuation allowance for deferred taxes, benefits under the Scientific Research and Experimental Development </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“SR&amp;ED”) program, and other contingencies. Management bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results could differ from these estimates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The full extent to which the COVID-19 pandemic may directly or indirectly impact the Company’s business, results of operations and financial condition, including revenues, expenses, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are evolving and highly uncertain, such as the duration and severity of outbreaks, including potential future waves or cycles, and the effectiveness of actions taken to contain and treat COVID-19. The Company considered the potential impact of COVID-19 when making certain estimates and judgments relating to the preparation of these interim condensed consolidated financial statements. While there was no material impact to the Company’s interim condensed consolidated financial statements as of and for the three and nine months ended September 30, 2022, the Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in a material impact to the Company’s consolidated financial statements in future reporting periods.</span></div>
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-47846000 usd
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-60579000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-185090000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-172691000 usd
CY2022Q3 zyme Fair Value Option Adjustment For Change In Fair Value Of Liability Classified Stock Options
FairValueOptionAdjustmentForChangeInFairValueOfLiabilityClassifiedStockOptions
-18000 usd
CY2021Q3 zyme Fair Value Option Adjustment For Change In Fair Value Of Liability Classified Stock Options
FairValueOptionAdjustmentForChangeInFairValueOfLiabilityClassifiedStockOptions
-4538000 usd
zyme Fair Value Option Adjustment For Change In Fair Value Of Liability Classified Stock Options
FairValueOptionAdjustmentForChangeInFairValueOfLiabilityClassifiedStockOptions
-217000 usd
zyme Fair Value Option Adjustment For Change In Fair Value Of Liability Classified Stock Options
FairValueOptionAdjustmentForChangeInFairValueOfLiabilityClassifiedStockOptions
-18270000 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-47864000 usd
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-65117000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-185307000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-190961000 usd
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
66477016 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51657371 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
64751271 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51483428 shares
CY2022Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1141 shares
CY2021Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
581530 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
4792 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
642501 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
66478157 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
52238901 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
64756063 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
52125929 shares
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.72
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.17
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.86
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.35
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.72
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.86
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.66
CY2022Q3 us-gaap Long Term Investments
LongTermInvestments
886000 usd
CY2021Q4 us-gaap Long Term Investments
LongTermInvestments
886000 usd
CY2021 us-gaap Number Of Reporting Units
NumberOfReportingUnits
1 reportingunit
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
CY2022Q3 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
317000 usd
CY2021Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
5174000 usd
CY2022Q3 zyme Accrued Research Expenses Current
AccruedResearchExpensesCurrent
35794000 usd
CY2021Q4 zyme Accrued Research Expenses Current
AccruedResearchExpensesCurrent
50963000 usd
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9364000 usd
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3346000 usd
CY2022Q3 zyme Accrued Legal And Professional Fees Current
AccruedLegalAndProfessionalFeesCurrent
2995000 usd
CY2021Q4 zyme Accrued Legal And Professional Fees Current
AccruedLegalAndProfessionalFeesCurrent
1064000 usd
CY2022Q3 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
3801000 usd
CY2021Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
2220000 usd
CY2022Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
52271000 usd
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
62767000 usd
CY2022Q3 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
1248000 usd
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
1498000 usd
CY2022Q3 zyme Liabilities From In Licensing Agreements
LiabilitiesFromInLicensingAgreements
850000 usd
CY2021Q4 zyme Liabilities From In Licensing Agreements
LiabilitiesFromInLicensingAgreements
1150000 usd
CY2022Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
155000 usd
CY2021Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
100000 usd
CY2022Q3 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
681000 usd
CY2021Q4 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
0 usd
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2934000 usd
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2748000 usd
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q3 zyme Warrants Exercised During Period
WarrantsExercisedDuringPeriod
3787737 shares
CY2022Q3 us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
3787675 shares
CY2022Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
57858000 usd
CY2022Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
74.00
zyme Share Based Payment Arrangement Individual Penalty Threshold Percentage
ShareBasedPaymentArrangementIndividualPenaltyThresholdPercentage
0.10
zyme Share Based Payment Arrangement Institutional Investors Penalty Threshold Percentage
ShareBasedPaymentArrangementInstitutionalInvestorsPenaltyThresholdPercentage
0.20
CY2006Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
0.20
CY2006Q3 zyme Share Based Compensation Arrangement By Share Based Payment Award Exercisable Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisablePeriod
P10Y
CY2018Q2 zyme Maximum Number Of Common Shares Reserved For Issuance
MaximumNumberOfCommonSharesReservedForIssuance
5686097 shares
CY2018Q1 zyme Common Stock Shares Issuable Upon Exercise Of Stock Option
CommonStockSharesIssuableUponExerciseOfStockOption
3686097 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
3275576 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
952632 shares
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
0.20
CY2006Q3 zyme Share Based Compensation Arrangement By Share Based Payment Award Exercisable Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisablePeriod
P10Y
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
116000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.773
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.807
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0198
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0098
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M12D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y18D
CY2006Q3 zyme Share Based Compensation Arrangement By Share Based Payment Award Exercisable Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisablePeriod
P10Y
zyme Share Based Compensation By Share Based Payment Award Unamortized Compensation Expense
ShareBasedCompensationByShareBasedPaymentAwardUnamortizedCompensationExpense
17309000 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P1Y7M9D
CY2022Q3 zyme Contributions To Employee Share Purchase Plan
ContributionsToEmployeeSharePurchasePlan
153000 usd
CY2021Q4 zyme Contributions To Employee Share Purchase Plan
ContributionsToEmployeeSharePurchasePlan
1243000 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2631000 usd
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4395000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9989000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6810000 usd
CY2022Q3 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
3000000 usd
CY2021Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0 usd
CY2022Q3 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
0 usd
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
0 usd
CY2021Q3 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
0 usd
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
0 usd
CY2022Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
1456000 usd
CY2021Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
813000 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
1817000 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
1185000 usd
CY2022Q3 zyme Other Nonoperating Income Expense Other
OtherNonoperatingIncomeExpenseOther
-98000 usd
CY2021Q3 zyme Other Nonoperating Income Expense Other
OtherNonoperatingIncomeExpenseOther
-4000 usd
zyme Other Nonoperating Income Expense Other
OtherNonoperatingIncomeExpenseOther
-15000 usd
zyme Other Nonoperating Income Expense Other
OtherNonoperatingIncomeExpenseOther
94000 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1358000 usd
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
809000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1802000 usd
CY2022Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
155000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1279000 usd
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4605000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1310000 usd
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
25334000 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
30923000 usd
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
29939000 usd
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
32233000 usd
CY2022Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
0 usd
CY2021Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
22000 usd
CY2022Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
155000 usd
CY2021Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
100000 usd
CY2021Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
122000 usd
CY2022Q3 zyme Lease Liability
LeaseLiability
30094000 usd
CY2021Q4 zyme Lease Liability
LeaseLiability
32355000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
3368000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Rolling Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths
5696000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Two
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo
4454000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Three
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree
4579000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Four
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour
4548000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Five
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive
3705000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due After Rolling Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive
12308000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
35290000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
5351000 usd
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
29939000 usd
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y9M18D
us-gaap Operating Lease Expense
OperatingLeaseExpense
6194000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
4030000 usd
zyme Fixed Lease Payment
FixedLeasePayment
5316000 usd
zyme Fixed Lease Payment
FixedLeasePayment
3756000 usd
us-gaap Variable Lease Payment
VariableLeasePayment
878000 usd
us-gaap Variable Lease Payment
VariableLeasePayment
274000 usd
CY2022Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
131727000 usd
CY2022Q3 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
1248000 usd
CY2021Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
112128000 usd
CY2021Q4 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
1498000 usd
CY2022Q2 zyme Contingent Consideration Liability Fair Value Disclosure
ContingentConsiderationLiabilityFairValueDisclosure
1248000 usd
CY2022Q3 zyme Contingent Consideration Fair Value Adjustments
ContingentConsiderationFairValueAdjustments
0 usd
CY2022Q3 zyme Contingent Consideration Liability Fair Value Disclosure Transfers
ContingentConsiderationLiabilityFairValueDisclosureTransfers
0 usd
CY2022Q3 zyme Contingent Consideration Liability Fair Value Disclosure
ContingentConsiderationLiabilityFairValueDisclosure
1248000 usd
CY2021Q4 zyme Contingent Consideration Liability Fair Value Disclosure
ContingentConsiderationLiabilityFairValueDisclosure
1498000 usd
zyme Contingent Consideration Fair Value Adjustments
ContingentConsiderationFairValueAdjustments
0 usd
zyme Contingent Consideration Liability Fair Value Disclosure Transfers
ContingentConsiderationLiabilityFairValueDisclosureTransfers
250000 usd
CY2022Q3 zyme Contingent Consideration Liability Fair Value Disclosure
ContingentConsiderationLiabilityFairValueDisclosure
1248000 usd
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6728000 usd
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
15614000 usd
CY2022Q3 zyme Net Monetary Assets Denominated In Foreign Currency
NetMonetaryAssetsDenominatedInForeignCurrency
477000 usd
CY2022Q3 zyme Net Monetary Assets Denominated In Foreign Currency
NetMonetaryAssetsDenominatedInForeignCurrency
653000 cad
us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.25
CY2022Q3 us-gaap Restructuring Reserve
RestructuringReserve
2674000 usd

Files In Submission

Name View Source Status
0001937653-22-000009-index-headers.html Edgar Link pending
0001937653-22-000009-index.html Edgar Link pending
0001937653-22-000009.txt Edgar Link pending
0001937653-22-000009-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
zyme-20220930.htm Edgar Link pending
zyme-20220930.xsd Edgar Link pending
zyme-20220930xex311.htm Edgar Link pending
zyme-20220930xex312.htm Edgar Link pending
zyme-20220930xex321.htm Edgar Link pending
zyme-20220930xex322.htm Edgar Link pending
zyme-20220930xex44.htm Edgar Link pending
zyme-20220930_cal.xml Edgar Link unprocessable
zyme-20220930_def.xml Edgar Link unprocessable
zyme-20220930_lab.xml Edgar Link unprocessable
zyme-20220930_pre.xml Edgar Link unprocessable
zyme-20220930_htm.xml Edgar Link completed